Cullinan Therapeutics, Inc. - 8-K Filing
Cullinan Therapeutics presented initial clinical data from its Phase 1 OUTRACE trials for CLN-978 at EULAR on June 6, 2026. The trial evaluated 29 patients with treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), showing dose-dependent B cell depletion in peripheral blood and tissue, along with clinical remissions in some cases. Safety was generally favorable up to a single target dose of 30 µg. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CGEM